6th Jun 2023 13:52
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Nominates a clinical candidate for its BVX001 programme after data from a clinical study into the Bi-Cygni antibody drug conjugate showed significant tumour regressions with no observed adverse effects in acute myeloid leukaemia.
BVX001 targets the cancer-specific twin antigen fingerprint of CD7+CD33+, which is present only on the leukaemic cancer cells enabling them to be selectively targeted, while leaving healthy white blood cells alone.
Chief Executive Officer Tiffany Thorn says: "We will continue to progress BVX001 through further preclinical studies towards obtaining regulatory approval to initiate human trials, while seeking suitable third-party partnerships to support manufacturing and clinical development activities as well as commercialisation of the asset."
Current stock price: 13.95 pence, up 7.3% on Tuesday
12-month change: down 39%
By Sabrina Penty, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
BVX.L